氯丙嗪对P-GP阳性肺癌患者化疗增效作用的研究

Research on the expression and clinical application of P-GP in pulmonary carcinoma

将 6 0例肺癌标本经免疫组化染色分为 P- GP阴性组 (N组 ,30例 )与阳性组 (P组 ,30例 ) ;P组中 2 0例 (P1 组 )化疗合用氯丙嗪 ,另 10例 (P2 组 )及 N组单纯化疗。于化疗前后检测尿肿瘤代谢产物。结果 :N组与 P组及 P1 组与 P2 组化疗前后有显著性差异 (P<0 .0 5 ) ;N组有效率为 83.3% (2 5 /30 ) ,P组为 5 6 .7% (17/30 ) ,P<0 .0 5 ;P1 组为 70 % (14/2 0 ) ,P2 组为 30 % (3/10 ) ,P<0 .0 5。随访表明 ,P1 组与 P2 组 1年 SR差异显著 (P<0 .0 5 ) ,2年及 3年无显著性差异 (P>0 .0 5 )。说明 P- GP阳性肺癌患者的化疗疗效差 ,生存率低 ,但合用氯丙嗪能增加化疗疗效、提高生存率。

specimens of pulmonary carcinoma were divided into p GP negative group(group N,30 cases)and P GP positive group(group P,30 cases)by immunohistochemical staining 20 cases of group P(group P 1)were treated with a combination of chemotherapy and chlorimipramine The other 10 cases of group P(group P 2)and all of group N were treated with chemotherapy only The results showed there were singificant difference between group N and group P or between group P 1 and group P 2 before and after chemotherapy(P<0 05) The effective rates of group N and group P were respectively 83 3%(25/30) and 56 7%(17/30)(P<0 05) And the effective rates of group P 1 and group P 2 were 70%(14/20)and 30%(3/10)(P<0 05) Follow up showed that SR were significantly different between group P 1 and group P 2 at one year’s time and were not signeficantly different at two years’time or at three years’time,which indicated the effect of chemotherapy on P GP positive pulmonary carcinoma patients was poor and the survival rate was low And the combination of chlorimipramine with chemotherapy could enhance therepeutic effect and increase survival rate